These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

480 related articles for article (PubMed ID: 25535951)

  • 1. Establishment of a general NAFLD scoring system for rodent models and comparison to human liver pathology.
    Liang W; Menke AL; Driessen A; Koek GH; Lindeman JH; Stoop R; Havekes LM; Kleemann R; van den Hoek AM
    PLoS One; 2014; 9(12):e115922. PubMed ID: 25535951
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reliability of the nonalcoholic steatohepatitis clinical research network and steatosis activity fibrosis histological scoring systems.
    Leung HH; Puspanathan P; Chan AW; Nik Mustapha NR; Wong VW; Chan WK
    J Gastroenterol Hepatol; 2022 Jun; 37(6):1131-1138. PubMed ID: 35362158
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-Throughput, Machine Learning-Based Quantification of Steatosis, Inflammation, Ballooning, and Fibrosis in Biopsies From Patients With Nonalcoholic Fatty Liver Disease.
    Forlano R; Mullish BH; Giannakeas N; Maurice JB; Angkathunyakul N; Lloyd J; Tzallas AT; Tsipouras M; Yee M; Thursz MR; Goldin RD; Manousou P
    Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2081-2090.e9. PubMed ID: 31887451
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progression of non-alcoholic steatosis to steatohepatitis and fibrosis parallels cumulative accumulation of danger signals that promote inflammation and liver tumors in a high fat-cholesterol-sugar diet model in mice.
    Ganz M; Bukong TN; Csak T; Saha B; Park JK; Ambade A; Kodys K; Szabo G
    J Transl Med; 2015 Jun; 13():193. PubMed ID: 26077675
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of Gene Expression Patterns Between Mouse Models of Nonalcoholic Fatty Liver Disease and Liver Tissues From Patients.
    Teufel A; Itzel T; Erhart W; Brosch M; Wang XY; Kim YO; von Schönfels W; Herrmann A; Brückner S; Stickel F; Dufour JF; Chavakis T; Hellerbrand C; Spang R; Maass T; Becker T; Schreiber S; Schafmayer C; Schuppan D; Hampe J
    Gastroenterology; 2016 Sep; 151(3):513-525.e0. PubMed ID: 27318147
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design and validation of a histological scoring system for nonalcoholic fatty liver disease.
    Kleiner DE; Brunt EM; Van Natta M; Behling C; Contos MJ; Cummings OW; Ferrell LD; Liu YC; Torbenson MS; Unalp-Arida A; Yeh M; McCullough AJ; Sanyal AJ;
    Hepatology; 2005 Jun; 41(6):1313-21. PubMed ID: 15915461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Automated computerized image analysis for the user-independent evaluation of disease severity in preclinical models of NAFLD/NASH.
    De Rudder M; Bouzin C; Nachit M; Louvegny H; Vande Velde G; Julé Y; Leclercq IA
    Lab Invest; 2020 Jan; 100(1):147-160. PubMed ID: 31506634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histopathology of nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Fukusato T
    World J Gastroenterol; 2014 Nov; 20(42):15539-48. PubMed ID: 25400438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors.
    Leite NC; Villela-Nogueira CA; Pannain VL; Bottino AC; Rezende GF; Cardoso CR; Salles GF
    Liver Int; 2011 May; 31(5):700-6. PubMed ID: 21457442
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathology of non-alcoholic fatty liver disease.
    Bedossa P
    Liver Int; 2017 Jan; 37 Suppl 1():85-89. PubMed ID: 28052629
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice.
    Tessitore A; Cicciarelli G; Del Vecchio F; Gaggiano A; Verzella D; Fischietti M; Mastroiaco V; Vetuschi A; Sferra R; Barnabei R; Capece D; Zazzeroni F; Alesse E
    BMC Cancer; 2016 Jan; 16():3. PubMed ID: 26728044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variation in diagnostic NAFLD/NASH read-outs in paired liver samples from rodent models.
    Jensen VS; Tveden-Nyborg P; Zacho-Rasmussen C; Quaade ML; Ipsen DH; Hvid H; Fledelius C; Wulff EM; Lykkesfeldt J
    J Pharmacol Toxicol Methods; 2020; 101():106651. PubMed ID: 31733366
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Presence and significance of microvesicular steatosis in nonalcoholic fatty liver disease.
    Tandra S; Yeh MM; Brunt EM; Vuppalanchi R; Cummings OW; Ünalp-Arida A; Wilson LA; Chalasani N
    J Hepatol; 2011 Sep; 55(3):654-659. PubMed ID: 21172393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Raman spectroscopy analysis of lipid droplets content, distribution and saturation level in Non-Alcoholic Fatty Liver Disease in mice.
    Kochan K; Maslak E; Krafft C; Kostogrys R; Chlopicki S; Baranska M
    J Biophotonics; 2015 Jul; 8(7):597-609. PubMed ID: 25346221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.
    McPherson S; Hardy T; Henderson E; Burt AD; Day CP; Anstee QM
    J Hepatol; 2015 May; 62(5):1148-55. PubMed ID: 25477264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease.
    Tallino S; Duffy M; Ralle M; Cortés MP; Latorre M; Burkhead JL
    J Nutr Biochem; 2015 Oct; 26(10):996-1006. PubMed ID: 26033743
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Non-alcoholic steatohepatitis in children.
    Nanda K
    Pediatr Transplant; 2004 Dec; 8(6):613-8. PubMed ID: 15598336
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Microvesicular steatosis: a missed item in the management of nonalcoholic fatty liver disease?
    Celebi G; Cicek AF; Gurel H; Genc H; Kirik A; Ercin CN; Dogru T
    Acta Gastroenterol Belg; 2020; 83(4):565-570. PubMed ID: 33321012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Controlled attenuation parameter for the detection and quantification of hepatic steatosis in nonalcoholic fatty liver disease.
    Chan WK; Nik Mustapha NR; Mahadeva S
    J Gastroenterol Hepatol; 2014; 29(7):1470-6. PubMed ID: 24548002
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep learning-based quantification of NAFLD/NASH progression in human liver biopsies.
    Heinemann F; Gross P; Zeveleva S; Qian HS; Hill J; Höfer A; Jonigk D; Diehl AM; Abdelmalek M; Lenter MC; Pullen SS; Guarnieri P; Stierstorfer B
    Sci Rep; 2022 Nov; 12(1):19236. PubMed ID: 36357500
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.